The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Richard B. Rothman

Clinical Psychopharmacology

IRP, NIDA, NIH, DHHS, Baltimore

Maryland

USA

[email]@*.nida.nih.gov

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Clinical Psychopharmacology, IRP, NIDA, NIH, DHHS, Baltimore, Maryland, USA. 2000 - 2010
  • Clinical Psychopharmacology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, USA. 1999 - 2006
  • National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, USA. 2000

References

  1. Evidence for noncompetitive modulation of substrate-induced serotonin release. Rothman, R.B., Baumann, M.H., Blough, B.E., Jacobson, A.E., Rice, K.C., Partilla, J.S. Synapse (2010) [Pubmed]
  2. Therapeutic potential of monoamine transporter substrates. Rothman, R.B., Baumann, M.H. Curr. Top. Med. Chem (2006) [Pubmed]
  3. Targeted screening for biogenic amine transporters: potential applications for natural products. Rothman, R.B., Baumann, M.H. Life Sci. (2005) [Pubmed]
  4. Substituted amphetamines that produce long-term serotonin depletion in rat brain ("neurotoxicity") do not decrease serotonin transporter protein expression. Rothman, R.B., Jayanthi, S., Cadet, J.L., Wang, X., Dersch, C.M., Baumann, M.H. Ann. N. Y. Acad. Sci. (2004) [Pubmed]
  5. (+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters. Rothman, R.B., Clark, R.D., Partilla, J.S., Baumann, M.H. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  6. Endogenous CART peptide regulates mu opioid and serotonin 5-HT(2A) receptors. Rothman, R.B., Vu, N., Wang, X., Xu, H. Peptides (2003) [Pubmed]
  7. In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. Rothman, R.B., Vu, N., Partilla, J.S., Roth, B.L., Hufeisen, S.J., Compton-Toth, B.A., Birkes, J., Young, R., Glennon, R.A. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  8. High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Rothman, R.B., Jayanthi, S., Wang, X., Dersch, C.M., Cadet, J.L., Prisinzano, T., Rice, K.C., Baumann, M.H. Synapse (2003) [Pubmed]
  9. Monoamine transporters and psychostimulant drugs. Rothman, R.B., Baumann, M.H. Eur. J. Pharmacol. (2003) [Pubmed]
  10. Serotonin releasing agents. Neurochemical, therapeutic and adverse effects. Rothman, R.B., Baumann, M.H. Pharmacol. Biochem. Behav. (2002) [Pubmed]
  11. Studies of the biogenic amine transporters. 10. Characterization of a novel cocaine binding site in brain membranes prepared from dopamine transporter knockout mice. Rothman, R.B., Carroll, F.I., Morales, M., Rowley, D.L., Rice, K.C., Dersch, C.M., Donovan, D.M. Synapse (2002) [Pubmed]
  12. Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Rothman, R.B., Katsnelson, M., Vu, N., Partilla, J.S., Dersch, C.M., Blough, B.E., Baumann, M.H. Eur. J. Pharmacol. (2002) [Pubmed]
  13. Endogenous corticotropin releasing factor regulates adrenergic and opioid receptors. Rothman, R.B., Vu, N., Xu, H., Baumann, M.H., Lu, Y.F. Peptides (2002) [Pubmed]
  14. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Rothman, R.B., Baumann, M.H., Dersch, C.M., Romero, D.V., Rice, K.C., Carroll, F.I., Partilla, J.S. Synapse (2001) [Pubmed]
  15. Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. Rothman, R.B., Partilla, J.S., Baumann, M.H., Dersch, C.M., Carroll, F.I., Rice, K.C. Synapse (2000) [Pubmed]
  16. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. Rothman, R.B., Gorelick, D.A., Heishman, S.J., Eichmiller, P.R., Hill, B.H., Norbeck, J., Liberto, J.G. J. Subst. Abuse. Treat (2000) [Pubmed]
  17. Methamphetamine dependence: medication development efforts based on the dual deficit model of stimulant addiction. Rothman, R.B., Partilla, J.S., Dersch, C.M., Carroll, F.I., Rice, K.C., Baumann, M.H. Ann. N. Y. Acad. Sci. (2000) [Pubmed]
  18. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Rothman, R.B., Ayestas, M.A., Dersch, C.M., Baumann, M.H. Circulation (1999) [Pubmed]
 
WikiGenes - Universities